❌

Normal view

Trustworthy Blockchain-based Federated Learning for Electronic Health Records: Securing Participant Identity with Decentralized Identifiers and Verifiable Credentials

arXiv:2602.02629v1 Announce Type: cross Abstract: The digitization of healthcare has generated massive volumes of Electronic Health Records (EHRs), offering unprecedented opportunities for training Artificial Intelligence (AI) models. However, stringent privacy regulations such as GDPR and HIPAA have created data silos that prevent centralized training. Federated Learning (FL) has emerged as a promising solution that enables collaborative model training without sharing raw patient data. Despite its potential, FL remains vulnerable to poisoning and Sybil attacks, in which malicious participants corrupt the global model or infiltrate the network using fake identities. While recent approaches integrate Blockchain technology for auditability, they predominantly rely on probabilistic reputation systems rather than robust cryptographic identity verification. This paper proposes a Trustworthy Blockchain-based Federated Learning (TBFL) framework integrating Self-Sovereign Identity (SSI) standards. By leveraging Decentralized Identifiers (DIDs) and Verifiable Credentials (VCs), our architecture ensures only authenticated healthcare entities contribute to the global model. Through comprehensive evaluation using the MIMIC-IV dataset, we demonstrate that anchoring trust in cryptographic identity verification rather than behavioral patterns significantly mitigates security risks while maintaining clinical utility. Our results show the framework successfully neutralizes 100% of Sybil attacks, achieves robust predictive performance (AUC = 0.954, Recall = 0.890), and introduces negligible computational overhead (
  • ✇STAT
  • STAT+: AI doctors are coming. Should FDA make sure they’re safe? Mario Aguilar
    When is an AI doctor a medical device? Call it a sign of things to come. A startup called Doctronic made a splash recently when it announced the use AI to renew prescriptions without clinician input in the state of Utah. Something didn’t sit right with me about the announcement. Sure it got approval from Utah, but why isn’t it a medical device subject to Food and Drug Administration review? The company claimed it was “the practice of medicine” and so exempt from FDA authority. That didn’t see
     

STAT+: AI doctors are coming. Should FDA make sure they’re safe?

3 February 2026 at 23:03

When is an AI doctor a medical device?

Call it a sign of things to come. A startup called Doctronic made a splash recently when it announced the use AI to renew prescriptions without clinician input in the state of Utah. Something didn’t sit right with me about the announcement. Sure it got approval from Utah, but why isn’t it a medical device subject to Food and Drug Administration review? The company claimed it was “the practice of medicine” and so exempt from FDA authority. That didn’t seem entirely right either. 

So I did some asking around and after talking to over a dozen executives, legal scholars, and policy experts, it turns out the question is not nearly as clear-cut as Doctronic would have us believe. Indeed, it appears the company may be planning to market a medical device without authorization. In my story, I explain the law and why it all matters.

Read more here

Continue to STAT+ to read the full story…

© Adobe

  • ✇STAT
  • STAT+: AI could soon renew prescriptions without clinician help. Should the FDA make sure it’s safe? Mario Aguilar
    Utah’s recent announcement that it was partnering with a health tech startup that will use artificial intelligence to renew drug prescriptions may offer a glimpse of the futuristic version of AI medicine that’s long been foretold by technologists and venture capitalists. But it’s only possible because of some pre-approved rule breaking — and may prove a broader test of the Food and Drug Administration’s authority to evaluate a new wave of clinical AI products, according to interviews with exe
     

STAT+: AI could soon renew prescriptions without clinician help. Should the FDA make sure it’s safe?

3 February 2026 at 17:30

Utah’s recent announcement that it was partnering with a health tech startup that will use artificial intelligence to renew drug prescriptions may offer a glimpse of the futuristic version of AI medicine that’s long been foretold by technologists and venture capitalists.

But it’s only possible because of some pre-approved rule breaking — and may prove a broader test of the Food and Drug Administration’s authority to evaluate a new wave of clinical AI products, according to interviews with executives and experts.

In January, Utah regulators said they had signed an agreement with a startup called Doctronic to launch an AI system that will perform a clinical evaluation of patients and, when deemed appropriate, renew some 200 common medications autonomously.

Continue to STAT+ to read the full story…

© Illustration: Camille MacMillin/STAT; Photos: Adobe

Digital intervention <i>mylovia</i> improves sexual functioning in women with sexual dysfunction in randomized controlled trial

npj Digital Medicine, Published online: 03 February 2026; doi:10.1038/s41746-026-02385-z

Digital intervention mylovia improves sexual functioning in women with sexual dysfunction in randomized controlled trial

Integrative proteogenomics maps multifactorial aetiology, progression and therapeutic vulnerabilities in gastric cancer

Gut. 2026 Jan 30:gutjnl-2025-337247. doi: 10.1136/gutjnl-2025-337247. Online ahead of print.

ABSTRACT

BACKGROUND: Gastric cancer, with disproportionately higher incidence in East Asia, arises from complex host-microbiome-environment interactions beyond Helicobacter pylori (HP) infection. However, the molecular architecture linking environmental carcinogens, microbial succession and host response remains unclear.

OBJECTIVE: To delineate multifactorial aetiologies and clinically actionable subtypes/biomarkers of gastric cancer through integrative proteogenomic, microbial and environmental exposure profiling.

DESIGN: We established a multiomics atlas of paired tumour, adjacent mucosa tissues and blood from 154 treatment-naïve Taiwanese patients, integrating whole-exome sequencing, RNA-seq, proteome and phosphoproteome profiling with carcinogen signatures, HP status, microbiome composition and refined anatomical mapping. Cell-based functional assays tested carcinogen effects. Microbial subtype was assessed in an independent cohort.

RESULTS: A polycyclic-aromatic-hydrocarbon signature, dibenz[a,h]acridine, emerged as a high-risk exposure promoting invasion, immune suppression and poor survival, significantly exceeding nitrosamine-linked risk in this cohort. Multilayer integration defined three initiation ecologies: HP-driven inflammatory, non-HP microbiome-enriched immune-silent and HP-free microbially depleted states. Among HP-negative tumours, a Streptococcus-enriched subtype associated with tight-junction (CLDN18.2/ZO-1/OCLN) disruption and epithelial-mesenchymal transition, whereas a subset of clinically aggressive cases retained CLDN18.2-high epithelial-stable subtype for therapeutic accessibility. An independent cohort revealed gastric juice-derived Streptococcus anginosus abundance inversely correlated with tight-junction proteins. Anatomical mapping reveals location-specific, sex-specific, subtype-specific oncogenic networks and kinase activity, including CDK4 activation in clinical biomarker-negative tumours. Decision-tree models combining exposure and proteome-immune states refined recurrence and survival prediction beyond stage.

CONCLUSION: This proteogenomic framework defines exposure-informed and microbiome-informed gastric cancer subtypes, providing a molecular schema for patient stratification, prevention and actionable therapeutic vulnerabilities.

PMID:41617485 | DOI:10.1136/gutjnl-2025-337247

Liquid biopsy biomarkers for accurate detection of malignant pulmonary nodules: a meta-analytic approach

Discov Oncol. 2026 Jan 29;17(1):178. doi: 10.1007/s12672-025-03646-1.

ABSTRACT

Pulmonary nodules are a common radiological finding that can be classified as either benign or Malignant, with significant clinical implications. The early detection of malignant nodules is critically important for improving the prognosis of lung cancer, which remains the leading cause of cancer-related mortality worldwide. Traditional imaging techniques have Limitations in accurately classifying pulmonary nodules. Liquid biopsy, a minimally invasive method that evaluates circulating components in the Blood, presents promising diagnostic potential in this context. This study aims to evaluate the diagnostic capacity of multiple liquid biopsy biomarkers for early and accurate differentiation between benign and Malignant pulmonary nodules. Accordingly, we conducted a comprehensive study involving a meta-analysis, selecting 16 eligible studies that utilised liquid biopsy to assess various circulating biomarkers in the diagnostic yield. The most significant results were linked to circulating free DNA (cfDNA). However, other components, including circulating tumour cells (CTCs), microRNAs/pfeRNAs, extracellular vesicles (EVs), serological markers, and imaging techniques, also provided valuable information. Similarly, integrating multi-omics data with machine learning models has been shown to enhance the ability to differentiate between benign and malignant pulmonary nodules, thereby supporting early diagnosis and improved management for patients with lung cancer.

PMID:41612093 | PMC:PMC12855667 | DOI:10.1007/s12672-025-03646-1

The Relationship Between Physician Self-Disclosure and Patient Acquisition in Digital Health Markets: Cross-Sectional Study

Background: Online health communities have evolved into digital marketplaces where physicians have to compete for patients. Existing research examines physician-patient dynamics through a patient-centric lens, treating physicians as passive recipients of ratings and reviews, while the strategic role of physician self-disclosure remains unexamined. This gap constrains a comprehensive understanding of how physicians can actively shape patient decisions, making the investigation of strategic self-disclosure imperative. Objective: This study aims to investigate the relationship between physician self-disclosure breadth (scope of information) and depth (detailed expertise) and patient decision-making, as well as whether regional digital health care level (DHL) moderates these relationships. Methods: We conducted a cross-sectional analysis of observational data to test these relationships. Data were collected from China’s online health care platform Haodf from September to December 2024. Self-disclosure breadth (including clinical performance, academic experience, and social reputation), self-disclosure depth (including expertise coverage, richness, and granularity), and patient decision-making (total visits) were captured through manual content coding and quantitative measurement. We used structured content analysis to extract the disclosure components, informational scope, and descriptive details of each profile. Then, using validated operational formulas, we calculated the composite indices for disclosure breadth and depth based on the coded dimensions. The study generated 1798 final physician samples with complete data across 14 focal variables. The hypotheses were tested using an ordinary least squares regression model, and 4 robustness checks were conducted, including variable substitution and different resampling techniques. Results: In the primary ordinary least squares regression models, self-disclosure breadth was significantly and positively associated with patient visits (β=0.255, 95% CI 0.054-0.456; P=.01), as was self-disclosure depth (β=0.098, 95% CI 0.030-0.167; P=.005). The breadth×DHL interaction was positive and significant (β=0.261, 95% CI 0.061-0.461; P=.01). Similarly, the depth×DHL interaction was positive and significant (β=0.070, 95% CI 0.002-0.138; P=.045). It should be noted that the association for self-disclosure breadth was stronger than that of self-disclosure depth. DHL strengthened the relationship between the disclosure strategies with patient visits. This contextual amplification indicates that DHL serves as a critical boundary condition, determining the degree to which physician self-disclosure strategies translate into patient acquisition outcomes. Conclusions: This study reconceptualizes physicians as strategic agents shaping patient decision-making through purposeful self-disclosure. Different from existing studies treating physicians as passive recipients of ratings and reviews, our research demonstrates that physicians can strategically shape patient acquisition through self-disclosure breadth and depth. This study brings new insights to digital health markets by demonstrating that self-disclosure operates as a viable patient acquisition mechanism, wherein the DHL acts as a critical boundary condition. The findings have real-world implications: (1) physicians can leverage evidence-based disclosure strategies, (2) platforms should implement context-adaptive features, and (3) policymakers should prioritize digital infrastructure investments to enhance physicians' competitive capabilities and patient decision-making quality.
  • ✇STAT
  • Opinion: Why I decided to share all my health information with ChatGPT Health Liz Salmi
    When I first heard about OpenAI’s ChatGPT Health, I felt a familiar itch. Since being diagnosed with a malignant brain tumor 18 years ago, at age 29, I’ve developed a deep curiosity about my own health. That curiosity has driven me to enroll in numerous studies, connect my health records to the NIH All of Us research program, and even donate my brain tissue for research-grade genomic sequencing.Read the rest…
     

Opinion: Why I decided to share all my health information with ChatGPT Health

29 January 2026 at 17:30

When I first heard about OpenAI’s ChatGPT Health, I felt a familiar itch.

Since being diagnosed with a malignant brain tumor 18 years ago, at age 29, I’ve developed a deep curiosity about my own health. That curiosity has driven me to enroll in numerous studies, connect my health records to the NIH All of Us research program, and even donate my brain tissue for research-grade genomic sequencing.

Read the rest…

© Adobe

Liquid biopsy in cancer diagnosis and prognosis: a paradigm shift in precision oncology

Front Mol Biosci. 2026 Jan 12;12:1708518. doi: 10.3389/fmolb.2025.1708518. eCollection 2025.

ABSTRACT

Liquid biopsy has emerged as a transformative tool in precision oncology, offering a minimally invasive approach for cancer detection, monitoring, and treatment guidance. Unlike traditional tissue biopsies, which are invasive and limited by tumor accessibility and sampling bias, liquid biopsy enables real-time tumor assessment through the analysis of circulating biomarkers in blood and other biofluids. This review provides a comprehensive overview of recent advances in liquid biopsy, with a focus on circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), non-coding RNAs, extracellular vesicles (exosomes), and secreted proteins. These biomarkers offer valuable insights into tumor biology, supporting applications in early diagnosis, prognosis, treatment response monitoring, and minimal residual disease detection across various cancer types. We also discuss state-of-the-art methodologies, including next-generation sequencing, digital PCR, microfluidics, proteomics, and emerging artificial intelligence-based approaches that enhance the sensitivity, specificity, and scalability of liquid biopsy assays. Clinical studies demonstrate the potential of liquid biopsy for tailoring targeted therapies, predicting resistance mechanisms, and identifying tumor recurrence earlier than conventional methods. Furthermore, FDA-approved assays and ongoing phase III and IV clinical trials highlight its growing integration into routine clinical practice. Beyond technical innovations, this review examines the global landscape of liquid biopsy, emphasizing opportunities and challenges for implementation across diverse healthcare settings. Disparities in access, particularly between high-income and low- and middle-income countries, underscore the need for strategies that ensure equitable adoption of liquid biopsy technologies worldwide. In summary, liquid biopsy represents a paradigm shift in oncology, bridging innovations in cancer diagnostics with clinical applications. By enabling dynamic, personalized, and less invasive cancer management, it holds great promise for improving patient outcomes and advancing precision medicine.

PMID:41602544 | PMC:PMC12832364 | DOI:10.3389/fmolb.2025.1708518

Tri-Reader: An Open-Access, Multi-Stage AI Pipeline for First-Pass Lung Nodule Annotation in Screening CT

arXiv:2601.19380v1 Announce Type: cross Abstract: Using multiple open-access models trained on public datasets, we developed Tri-Reader, a comprehensive, freely available pipeline that integrates lung segmentation, nodule detection, and malignancy classification into a unified tri-stage workflow. The pipeline is designed to prioritize sensitivity while reducing the candidate burden for annotators. To ensure accuracy and generalizability across diverse practices, we evaluated Tri-Reader on multiple internal and external datasets as compared with expert annotations and dataset-provided reference standards.

Is On-Policy Data always the Best Choice for Direct Preference Optimization-based LM Alignment?

arXiv:2508.10530v2 Announce Type: replace Abstract: The alignment of language models~(LMs) with human preferences is critical for building reliable AI systems. The problem is typically framed as optimizing an LM policy to maximize the expected reward that reflects human preferences. Recently, Direct Preference Optimization~(DPO) was proposed as a LM alignment method that directly optimize the policy from static preference data, and further improved by incorporating on-policy sampling~(i.e., preference candidates generated during the training loop) for better LM alignment. However, we show on-policy data is not always optimal, with systematic effectiveness difference emerging between static and on-policy preference candidates. For example, on-policy data can result in a $3\times$ effectiveness compared with static data for Llama-3, and a $0.4\times$ effectiveness for Zephyr. To explain the phenomenon, we propose the alignment stage assumption, which divides the alignment process into two distinct stages: the preference injection stage, which benefits from diverse data, and the preference fine-tuning stage, which favors high-quality data. Through theoretical and empirical analysis, we characterize these stages and propose an effective algorithm to identify the boundaries between them. We perform experiments on $5$ models~(Llama, Zephyr, Phi-2, Qwen, Pythia) and $2$ alignment methods~(DPO, SLiC-HF) to show the generalizability of alignment stage assumption and the effectiveness of the boundary measurement algorithm.

Demystifying the Roles of LLM Layers in Retrieval, Knowledge, and Reasoning

arXiv:2510.02091v4 Announce Type: replace Abstract: Recent studies suggest that the deeper layers of Large Language Models (LLMs) contribute little to representation learning and can often be removed without significant performance loss. However, such claims are typically drawn from narrow evaluations and may overlook important aspects of model behavior. In this work, we present a systematic study of depth utilization across diverse dimensions, including evaluation protocols, task categories, and model architectures. Our analysis confirms that very deep layers are generally less effective than earlier ones, but their contributions vary substantially with the evaluation setting. Under likelihood-based metrics without generation, pruning most layers preserves performance, with only the initial few being critical. By contrast, generation-based evaluation uncovers indispensable roles for middle and deeper layers in enabling reasoning and maintaining long-range coherence. We further find that knowledge and retrieval are concentrated in shallow components, whereas reasoning accuracy relies heavily on deeper layers -- yet can be reshaped through distillation. These results highlight that depth usage in LLMs is highly heterogeneous and context-dependent, underscoring the need for task-, metric-, and model-aware perspectives in both interpreting and compressing large models.

Rethinking the AI Scientist: Interactive Multi-Agent Workflows for Scientific Discovery

arXiv:2601.12542v2 Announce Type: replace Abstract: Artificial intelligence systems for scientific discovery have demonstrated remarkable potential, yet existing approaches remain largely proprietary and operate in batch-processing modes requiring hours per research cycle, precluding real-time researcher guidance. This paper introduces Deep Research, a multi-agent system enabling interactive scientific investigation with turnaround times measured in minutes. The architecture comprises specialized agents for planning, data analysis, literature search, and novelty detection, unified through a persistent world state that maintains context across iterative research cycles. Two operational modes support different workflows: semi-autonomous mode with selective human checkpoints, and fully autonomous mode for extended investigations. Evaluation on the BixBench computational biology benchmark demonstrated state-of-the-art performance, achieving 48.8% accuracy on open response and 64.4% on multiple-choice evaluation, exceeding existing baselines by 14 to 26 percentage points. Analysis of architectural constraints, including open access literature limitations and challenges inherent to automated novelty assessment, informs practical deployment considerations for AI-assisted scientific workflows.

AI-generated data contamination erodes pathological variability and diagnostic reliability

arXiv:2601.12946v3 Announce Type: replace-cross Abstract: Generative artificial intelligence (AI) is rapidly populating medical records with synthetic content, creating a feedback loop where future models are increasingly at risk of training on uncurated AI-generated data. However, the clinical consequences of this AI-generated data contamination remain unexplored. Here, we show that in the absence of mandatory human verification, this self-referential cycle drives a rapid erosion of pathological variability and diagnostic reliability. By analysing more than 800,000 synthetic data points across clinical text generation, vision-language reporting, and medical image synthesis, we find that models progressively converge toward generic phenotypes regardless of the model architecture. Specifically, rare but critical findings, including pneumothorax and effusions, vanish from the synthetic content generated by AI models, while demographic representations skew heavily toward middle-aged male phenotypes. Crucially, this degradation is masked by false diagnostic confidence; models continue to issue reassuring reports while failing to detect life-threatening pathology, with false reassurance rates tripling to 40%. Blinded physician evaluation confirms that this decoupling of confidence and accuracy renders AI-generated documentation clinically useless after just two generations. We systematically evaluate three mitigation strategies, finding that while synthetic volume scaling fails to prevent collapse, mixing real data with quality-aware filtering effectively preserves diversity. Ultimately, our results suggest that without policy-mandated human oversight, the deployment of generative AI threatens to degrade the very healthcare data ecosystems it relies upon.

Products, Performance, and Technological Development of Ambulatory Oxygen Therapy Devices: Scoping Review

Background: Ambulatory oxygen therapy is prescribed for patients with chronic lung diseases who experience exertional hypoxemia. However, available devices may not adequately meet user requirements, and their performance characteristics are heterogeneous. Objective: This study aims to identify devices available for delivery of ambulatory oxygen therapy, the technologies that they use to generate oxygen, the performance characteristics of each device, and the development status. Methods: We used medical and engineering databases to identify peer-reviewed papers (eg, MEDLINE, IEEE). Gray literature was used to identify additional descriptions of ambulatory oxygen devices in military medicine, space exploration, or patents. The last search was conducted in September 2025. Documents that described a device that can deliver oxygen in an ambulatory context (defined as weighing less than 10 kg) and were written in English were included. Search results were screened for inclusion by 2 independent reviewers. Data were synthesized by descriptively mapping the performance of each product, the technology used, and the development status of emerging technologies. Results: From 9702 records identified, a total of 166 met eligibility criteria (106 scientific publications and 60 gray literature). We identified 33 portable oxygen concentrators (POCs; 29 commercially available), 10 oxygen cylinders, and 6 portable liquid oxygen (LOX) devices. The POC products showed a trade-off between portability and oxygen delivery capacity (maximum flow rate ranging from 2.0 to 6.0 L/min; device weight ranging from 1.0 to 9.1 kg). Pressure swing adsorption with zeolite was the most common oxygen generation technology in POCs on the market. The mean maximum continuous operating time of POCs was 3.8 hours. Two prototype POCs (maximum flow rate of 4-6 L/min and device weight of 8-9 kg) were developed for space exploration using modified adsorbents. LOX devices were the lightest and had the longest continuous operating time. Innovations in delivery included the downsizing of a POC by using nanozeolite as an adsorbent and pulse oximeter oxygen saturation (SpO2)–targeted automatic titration of oxygen delivery based on the user’s SpO2. Conclusions: This scoping review is the first study to integrate medical, engineering, and gray literature on ambulatory oxygen devices and their development. Although prior literature has narratively explained the products and technologies, no previous research has systematically investigated them. This review showed that POCs available to consumers may not meet the needs of patients in terms of flow rate, portability, and operating time. LOX devices offered superior performance but are limited by high costs. Limitations of this review include the difficulty of comparing product performance across oxygen delivery settings and that the records were largely obtained from English-language sources. Innovation in ambulatory oxygen technology has been limited over the past decade, highlighting urgent need for research and development of new lightweight devices with higher oxygen delivery. Clinical Trial: OSF Registries 10.17605/OSF.IO/QS7FX; https://osf.io/qs7fx

Exploring the key molecular mechanisms and immune microenvironment of oxidative stress-related pathways in pancreatic neuroendocrine tumor combining scRNA-seq and bulk RNA

Discov Oncol. 2026 Jan 27. doi: 10.1007/s12672-026-04515-1. Online ahead of print.

ABSTRACT

BACKGROUND: Pancreatic neuroendocrine tumor (pNET) is a heterogeneous tumor originating from pancreatic endocrine cells. Emerging evidence suggests that oxidative stress plays a crucial role in pNET pathogenesis, yet the precise molecular mechanisms and their interplay with the tumor microenvironment remain unclear. This study aims to systematically elucidate how oxidative stress-related pathways drive pNET progression through an integrated multi-omics approach.

METHODS: We designed a three-tier analytical strategy to address interconnected scientific questions. First, to identify which oxidative stress-related genes are dysregulated in pNET, we performed differential expression analysis and weighted gene co-expression network analysis (WGCNA) on the GSE73338 dataset (63 pNET samples, 5 controls), intersecting the. results with oxidative stress gene sets to obtain 71 candidate genes. Second, to understand the functional implications of these genes, we conducted GO/KEGG enrichment analysis and constructed protein-protein interaction (PPI) networks, from which we identified BCL2L1 and PHGDH as key hub genes using three independent algorithms. We then assessed their diagnostic value through ROC analysis and built a prognostic nomogram model. Third, to explore how these key genes influence the tumor microenvironment, we performed immune infiltration analysis using CIBERSORTx. Fourth, to reveal upstream regulatory mechanisms, we constructed ceRNA networks and predicted transcription factors. Fifth, to identify potential therapeutic interventions, we conducted drug prediction and molecular docking analyses. Finally, to validate our findings at cellular resolution and understand cellular heterogeneity, we analyzed single-cell RNA sequencing data from GSE256136 (20 samples), identifying cell types, quantifying cell-cell communications, and confirming key gene expression patterns across different cell populations.

RESULTS: Our systematic analysis revealed that oxidative stress-related genes in pNET were significantly enriched in the PI3K-Akt signaling pathway, cysteine and methionine metabolism, and HIF-1 signaling pathway. BCL2L1 and PHGDH emerged as central regulators with excellent diagnostic performance (AUC > 0.9). Immune infiltration analysis demonstrated significant alterations in activated dendritic cells, memory B cells, and resting NK cells, which correlated strongly with BCL2L1 and PHGDH expression, suggesting these genes link oxidative stress to immune dysfunction. The ceRNA network centered on KCNQ1OT1 and hsa-miR-15a-5p revealed multi-layered transcriptional and post-transcriptional regulation. Drug prediction identified sertindole and cabozantinib as promising therapeutic candidates. Single-cell analysis identified 11 cell types and confirmed that endocrine cells are the primary site of BCL2L1 and PHGDH dysregulation, with extensive crosstalk between endocrine cells and T cells potentially mediating immune evasion.

CONCLUSION: Through integrated multi-omics analysis, we established that oxidative stress pathways may drive pNET progression through a coordinated mechanism involving metabolic reprogramming (via BCL2L1 and PHGDH downregulation), immune microenvironment remodeling (through altered dendritic cell and NK cell function), and complex regulatory networks. BCL2L1 and PHGDH represent potential diagnostic biomarkers and candidate therapeutic targets that require experimental validation, providing new directions for precision medicine in pNET.

PMID:41591671 | DOI:10.1007/s12672-026-04515-1

China’s innovation in translational medicine: rethinking early-stage clinical development

Nature Biotechnology, Published online: 27 January 2026; doi:10.1038/s41587-025-02998-x

As pressure mounts globally on drug pricing and development cost continues to rise, clinicians and translational scientists in biotech, academia and biopharma companies are re-evaluating when, where and how to launch early clinical programs. These initial patient data become critical to de-risk development programs and allow developers to deploy their limited time and resources on the most promising drugs. We evaluate four fundamental shifts in drug development that appear to be unfolding and may well become critical to future global biopharma success: use of large-scale high quality cohort studies, sponsor-driven investigator-initiated trials, the integration of affordable artificial intelligence with extensive high quality data registries, and China’s focus on precision medicine. —

HyCARD-Net: A Synergistic Hybrid Intelligence Framework for Cardiovascular Disease Diagnosis

arXiv:2601.17767v1 Announce Type: new Abstract: Cardiovascular disease (CVD) remains the foremost cause of mortality worldwide, underscoring the urgent need for intelligent and data-driven diagnostic tools. Traditional predictive models often struggle to generalize across heterogeneous datasets and complex physiological patterns. To address this, we propose a hybrid ensemble framework that integrates deep learning architectures, Convolutional Neural Networks (CNN) and Long Short-Term Memory (LSTM), with classical machine learning algorithms, including K-Nearest Neighbor (KNN) and Extreme Gradient Boosting (XGB), using an ensemble voting mechanism. This approach combines the representational power of deep networks with the interpretability and efficiency of traditional models. Experiments on two publicly available Kaggle datasets demonstrate that the proposed model achieves superior performance, reaching 82.30 percent accuracy on Dataset I and 97.10 percent on Dataset II, with consistent gains in precision, recall, and F1-score. These findings underscore the robustness and clinical potential of hybrid AI frameworks for predicting cardiovascular disease and facilitating early intervention. Furthermore, this study directly supports the United Nations Sustainable Development Goal 3 (Good Health and Well-being) by promoting early diagnosis, prevention, and management of non-communicable diseases through innovative, data-driven healthcare solutions.

Coronary Artery Segmentation and Vessel-Type Classification in X-Ray Angiography

arXiv:2601.17429v1 Announce Type: cross Abstract: X-ray coronary angiography (XCA) is the clinical reference standard for assessing coronary artery disease, yet quantitative analysis is limited by the difficulty of robust vessel segmentation in routine data. Low contrast, motion, foreshortening, overlap, and catheter confounding degrade segmentation and contribute to domain shift across centers. Reliable segmentation, together with vessel-type labeling, enables vessel-specific coronary analytics and downstream measurements that depend on anatomical localization. From 670 cine sequences (407 subjects), we select a best frame near peak opacification using a low-intensity histogram criterion and apply joint super-resolution and enhancement. We benchmark classical Meijering, Frangi, and Sato vesselness filters under per-image oracle tuning, a single global mean setting, and per-image parameter prediction via Support Vector Regression (SVR). Neural baselines include U-Net, FPN, and a Swin Transformer, trained with coronary-only and merged coronary+catheter supervision. A second stage assigns vessel identity (LAD, LCX, RCA). External evaluation uses the public DCA1 cohort. SVR per-image tuning improves Dice over global means for all classical filters (e.g., Frangi: 0.759 vs. 0.741). Among deep models, FPN attains 0.914+/-0.007 Dice (coronary-only), and merged coronary+catheter labels further improve to 0.931+/-0.006. On DCA1 as a strict external test, Dice drops to 0.798 (coronary-only) and 0.814 (merged), while light in-domain fine-tuning recovers to 0.881+/-0.014 and 0.882+/-0.015. Vessel-type labeling achieves 98.5% accuracy (Dice 0.844) for RCA, 95.4% (0.786) for LAD, and 96.2% (0.794) for LCX. Learned per-image tuning strengthens classical pipelines, while high-resolution FPN models and merged-label supervision improve stability and external transfer with modest adaptation.
❌